Search results for "Intensive Care"

showing 10 items of 2793 documents

Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)

2021

Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity and mortality across Europe. Much of these diseases burden is modifiable, in particular by lipid-lowering therapy (LLT). Current guidelines are based on the sound premise that with respect to low density lipoprotein cholesterol (LDL-C), “lower is better for longer”, and the recent data have strongly emphasized the need of also “the earlier the better”. In addition to statins, which have been available for several decades, the availability of ezetimibe and inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) are additional very effective approa…

0301 basic medicineRMmedicine.medical_specialtyCombination therapyPCSK9 inhibitoreffectivenessTreatment goalsLipid-lowering therapy03 medical and health sciences0302 clinical medicineEzetimibemedicineHumansAcute Coronary SyndromeCombination therapyIntensive care medicinePharmacologyStatins.business.industryAtherosclerotic cardiovascular diseaseAnticholesteremic AgentsPCSK9StatinsEffectiveneDisease ManagementAtherosclerosisEzetimibeLipids030104 developmental biologyPCSK9 inhibitors030220 oncology & carcinogenesisPosition paperSafetybusinessVery high riskmedicine.drug
researchProduct

Influenza vaccine effectiveness among high-risk groups: a systematic literature review and metaanalysis of case-control and cohort studies

2017

Vaccination represents the most effective intervention to prevent infection, hospitalization and mortality due to influenza. This meta-analysis quantifies data reporting influenza vaccine effectiveness (VE) on influenza visits and hospitalizations of case-control and cohort studies among high-risk groups. A systematic literature review including original articles published between 2007 and 2016, using a protocol registered on Prospero with No. 42017054854, and a meta-analysis were conducted. For three high-risk groups (subjects with underlying health conditions, pregnant women and health care workers) only a qualitative evaluation was carried out. The VE quantitative analysis demonstrated a…

0301 basic medicineReviewSettore MED/42 - Igiene Generale E ApplicataCohort Studies0302 clinical medicinePregnancyvaccineHealth careImmunology and AllergyMedicine030212 general & internal medicineData reportingChildAged 80 and overVaccinationMiddle AgedVaccinationHospitalizationSystematic reviewInfluenza VaccinesMeta-analysisChild PreschoolFemaleelderly subjectsinfluenzaCohort studyAdultRiskmedicine.medical_specialtyInfluenza vaccine effectiveness children elderly subjects chronic disease pregnancy health care worker hospitalization visit.AdolescentInfluenza vaccine030106 microbiologyImmunologyeffectiveness03 medical and health sciencesYoung AdultchildrenInfluenza HumanHumansIntensive care medicineAgedPharmacologybusiness.industryPublic healthInfanthealth care workerCase-Control StudiesEmergency medicinebusinessvisitchronic disease
researchProduct

What is the risk of acquiring bacteria from prior intensive care unit bed occupants?

2017

0301 basic medicineRiskmedicine.medical_specialtyLetterMulti drug resistant bacteriaSepsi030106 microbiologyIntensive Care UnitBacterial contamination; Infection; Multi-drug resistant bacteria; SepsisBacterial contamination; Infection; Multi-drug resistant bacteria; Sepsis; Critical Care and Intensive Care MedicineMulti-drug resistant bacteriaCritical Care and Intensive Care Medicinelaw.inventionSepsis03 medical and health sciences0302 clinical medicinelawPatients' RoomSepsisPatients' RoomsAnti-Bacterial AgentHumansMedicineMultidrug-resistant gram-negative bacteriaMED/41 - ANESTESIOLOGIAIntensive care medicineCross InfectionInfection Controlbiologybusiness.industry030208 emergency & critical care medicinemedicine.diseasebiology.organism_classificationIntensive care unitAnti-Bacterial AgentsIntensive Care UnitsEquipment ContaminationbusinessInfectionBacteriaBacterial contaminationHuman
researchProduct

Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris

2018

Abstract Candida spp. infections are a major cause of morbidity and mortality in critically ill patients. Candida auris is an emerging multi-drug-resistant fungus that is rapidly spreading worldwide. Since the first reports in 2009, many isolates across five continents have been identified as agents of hospital-associated infections. Independent and simultaneous outbreaks of C. auris are becoming a major concern for healthcare and scientific community. Moreover, laboratory misidentification and multi-drug-resistant profiles, rarely observed for other non-albicans Candida species, result in difficult eradication and frequent therapeutic failures of C. auris infections. The aim of this review…

0301 basic medicineSettore MED/07 - Microbiologia E Microbiologia Clinicamedicine.medical_specialty030106 microbiologySettore MED/41 - AnestesiologiaVirulenceAntimicrobial resistanceCritical Care and Intensive Care MedicineMicrobiology03 medical and health sciencesInvasive fungal infectionAntibiotic resistanceEpidemiologymedicineCandidaResistance (ecology)business.industryCritically illlcsh:Medical emergencies. Critical care. Intensive care. First aidCandidemiaOutbreakAntifungal resistancelcsh:RC86-88.9Candida aurisCandida sppC. aurisC. auris Candida Candidemia Invasive fungal infection Antimicrobial resistance Antifungal resistancebusinessJournal of Intensive Care
researchProduct

Clinical Characteristics and Outcomes of Patients with COVID-19 Infection: The Results of the SARS-RAS Study of the Italian Society of Hypertension

2021

: The COVID-19 infection has rapidly spread around the world and a second wave is sweeping in many countries. Different clinical and epidemiological aspects characterize the disease and their understanding is necessary to better face the management of the pandemic in progress. The Italian society of arterial hypertension with the SARS-RAS study has contributed significantly to the knowledge of the interaction between inhibition of the renin-angiotensin system and COVID-19 infection. Furthermore, the study results help to understand some of the main aspects related to mortality and morbidity deriving from the infection through a multicentre analysis throughout the national territory.

0301 basic medicineSettore MED/09 - Medicina InternaCross-sectional studyDiseaseComorbiditySeverity of Illness IndexComorbiditiesRenin-Angiotensin System0302 clinical medicineRisk FactorsSex-differences.EpidemiologyPandemicFrailtySars-Cov2Treatment OutcomeItalyAnti-hypertensive therapy; comorbidities; frailty; Sars-Cov2; sex-differencesHypertensionComorbiditiePosition PaperRisk assessmentCardiology and Cardiovascular Medicinemedicine.medical_specialtySex-differenceRisk Assessment03 medical and health sciencesPharmacotherapySex FactorsSeverity of illnessmedicineAnti-hypertensive therapy Sars-Cov2 Frailty Comorbidities Sex-differencesInternal MedicineHumansArterial PressureAnti-hypertensive therapy Comorbidities Frailty Sars-Cov2 Sex-differencesIntensive care medicineAnti-hypertensive therapyAntihypertensive AgentsAnti-hypertensive therapy; Comorbidities; Frailty; Sars-Cov2; Sex-differences; Antihypertensive Agents; Arterial Pressure; COVID-19; Comorbidity; Cross-Sectional Studies; Frailty; Humans; Hypertension; Italy; Renin-Angiotensin System; Risk Assessment; Risk Factors; Severity of Illness Index; Sex Factors; Treatment OutcomeSettore MED/14 - Nefrologiabusiness.industryCOVID-19medicine.diseaseComorbiditySex-differences030104 developmental biologyCross-Sectional Studiesbusiness030217 neurology & neurosurgery
researchProduct

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

2020

Proper trial design is critical for the success of clinical investigations. Hepatocellular carcinoma (HCC) is a complex disease that has several unique properties. In 2008, after the approval of sorafenib, a panel of experts proposed guidelines for trial design and endpoints in HCC that have been instrumental during the last decade and provided a framework to allow an homogeneous analysis of reported investigations. Since then, several phase III studies have been reported and novel challenges have emerged. A panel of experts conveyed by AASLD organized a Special Topic Conference on trial design and endpoints to address those emerging challenges. This review summarizes the analysis and concl…

0301 basic medicineSorafenibmedicine.medical_specialtyCarcinoma HepatocellularConsensusEndpoint DeterminationMEDLINEDisease03 medical and health sciences0302 clinical medicinemedicineHumansProgression-free survivalChemoembolization TherapeuticLiquid biopsyIntensive care medicineAdverse effectImmune Checkpoint InhibitorsProtein Kinase InhibitorsClinical Trials as TopicHepatologybusiness.industryLiver NeoplasmsLiquid Biopsymedicine.diseaseLiver TransplantationClinical trial030104 developmental biologyResearch DesignHepatocellular carcinoma030211 gastroenterology & hepatologybusinessmedicine.drugHepatology
researchProduct

Thrombo-Inflammation in Cardiovascular Disease

2020

AbstractThrombo-inflammation describes the complex interplay between blood coagulation and inflammation that plays a critical role in cardiovascular diseases. The third Maastricht Consensus Conference on Thrombosis assembled basic, translational, and clinical scientists to discuss the origin and potential consequences of thrombo-inflammation in the etiology, diagnostics, and management of patients with cardiovascular disease, including myocardial infarction, stroke, and peripheral artery disease. This article presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following topics: (1) challenges of the endothelial cell barrier; (2) circulating …

0301 basic medicineVENOUS THROMBOSISmedicine.medical_specialtypulmonary embolismNeutrophilsIschemiaISCHEMIA-REPERFUSION INJURYDisease030204 cardiovascular system & hematologyCATHETER-DIRECTED THROMBOLYSIS03 medical and health sciences0302 clinical medicinePERIPHERAL ARTERY-DISEASEMedicineAnimalsHumansPlateletMyocardial infarctionDEEP-VEIN THROMBOSIScoagulationIntensive care medicineStrokeBlood CoagulationExpert Testimonythrombosisbusiness.industryACUTE CORONARY SYNDROMESNEUTROPHIL EXTRACELLULAR TRAPSHematologyNeutrophil extracellular trapsVenous ThromboembolismACTIVATABLE FIBRINOLYSIS INHIBITORmedicine.diseaseAtherosclerosisThrombosisstrokeImmunity Innate3. Good healthVenous thrombosis030104 developmental biologymyocardial infarctionTISSUE FACTORCardiovascular DiseasesinflammationplateletsEndothelium VascularbusinessSUBCLINICAL LEAFLET THROMBOSISThrombosis and Haemostasis
researchProduct

Vitamin D and Cardiovascular Health

2021

The principal source of vitamin D in humans is its biosynthesis in the skin through a chemical reaction dependent on sun exposure. In lesser amounts, the vitamin can be obtained from the diet, mostly from fatty fish, fish liver oil and mushrooms. Individuals with vitamin D deficiency, defined as a serum level of 25 hydroxyvitamin D < 20 ng/dl, should be supplemented. Vitamin D deficiency is a prevalent global problem caused mainly by low exposure to sunlight. The main role of 1,25 dihydroxyvitamin D is the maintenance of calcium and phosphorus homeostasis. However, vitamin D receptors are found in most human cells and tissues, indicating many extra-skeletal effects of the vitamin, particula…

0301 basic medicineVitaminmedicine.medical_specialtyVitamina DEnfermedad cardiovascularchemistry.chemical_element030209 endocrinology & metabolismCalciumCritical Care and Intensive Care Medicinemedicine.disease_causevitamin D deficiencyNitric oxide03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemInternal medicineHipertensiónmedicineVitamin D and neurologyHumansSupplementsVitamin D030109 nutrition & dieteticsNutrition and DieteticsEnfermedad coronariabusiness.industryEndothelial functionVitamin D Deficiencymedicine.diseaseCardiovascular diseaseCoronary heart diseaseEndocrinologyDietéticachemistryCardiovascular DiseasesNutriciónHypertensionNarrative ReviewbusinessHomeostasisOxidative stress
researchProduct

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

2020

AbstractCoronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct…

0301 basic medicinecoronavirusAnti-Inflammatory AgentsReview Article030204 cardiovascular system & hematologymedicine.disease_causelaw.inventioncovid190302 clinical medicineRandomized controlled triallawAntithromboticPandemicViralanticoagulationCoronavirusGlycosaminoglycansAnimals; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Fibrinolytic Agents; Glycosaminoglycans; Hemostasis; Humans; Inflammation; Pandemics; Platelet Aggregation Inhibitors; Pneumonia Viral; Thrombosiscoronavirus 2immunomodulatorHematologyHeparinThrombosisantithrombinCoronavirus Infectionsmedicine.drugmedicine.medical_specialtyPneumonia Viralcoronavirus disease 2019 thrombosis inflammation fibrinolytic therapy anticoagulation immunomodulator antithrombin thrombomodulinAntiviral Agents03 medical and health sciencescoronavirus disease 2019BetacoronavirusFibrinolytic AgentsmedicineAnimalsHumansthrombosis COVID-19 coronavirusDosingIntensive care medicinePandemicsthrombosisInflammationHemostasisbusiness.industrySARS-CoV-2AnticoagulantsCOVID-19ThrombosisPneumoniathrombomodulinmedicine.diseaseReview articleCOVID-19 Drug Treatment030104 developmental biologyinflammationfibrinolytic therapybusinessPlatelet Aggregation InhibitorsThrombosis and haemostasis
researchProduct

Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH sur…

2017

Background Scant information is available about how transplant centers are managing their use of quantitative molecular testing (QNAT) assays for active cytomegalovirus (CMV) infection monitoring in solid organ transplant (SOT) recipients. The current study was aimed at gathering information on current practices in the management of CMV infection across European centers in the era of molecular testing assays. Methods A questionnaire-based cross-sectional survey study was conducted by the European Study Group of Infections in Immunocompromised Hosts (ESGICH) of the Society of Clinical Microbiology and Infectious Diseases (ESCMID). The invitation and a weekly reminder with a personal link to …

0301 basic medicinecytomegalovirus; solid organ transplantation; survey.cytomegalovirus ; solid organ transplantation ; surveyCross-sectional studyCytomegalovirusTransplantsPractice Patterns030230 surgeryOrgan transplantationlaw.invention0302 clinical medicinePostoperative Complicationslaw03.02. Klinikai orvostanViralPractice Patterns Physicians'solid organ transplantationPolymerase chain reactionViral LoadEuropeInfectious DiseasesCytomegalovirus InfectionsPractice Guidelines as Topiccytomegalovirus; solid organ transplantation; survey; Antibiotic Prophylaxis; Antiviral Agents; Cross-Sectional Studies; Cytomegalovirus; Cytomegalovirus Infections; DNA Viral; Europe; Guideline Adherence; Health Care Surveys; Humans; Immunocompromised Host; Immunosuppression; Organ Transplantation; Postoperative Complications; Practice Guidelines as Topic; Practice Patterns Physicians'; Real-Time Polymerase Chain Reaction; Transplant Recipients; Transplants; Viral LoadGuideline Adherencecytomegalovirus; solid organ transplantation; survey; Antibiotic Prophylaxis; Antiviral Agents; Cross-Sectional Studies; Cytomegalovirus; Cytomegalovirus Infections; DNA Viral; Europe; Guideline Adherence; Health Care Surveys; Humans; Immunocompromised Host; Immunosuppression; Organ Transplantation; Postoperative Complications; Practice Guidelines as Topic; Practice Patterns Physicians'; Real-Time Polymerase Chain Reaction; Transplant Recipients; Transplants; Viral Load; Transplantation; Infectious Diseasesmedicine.medical_specialty030106 microbiologyCongenital cytomegalovirus infectionReal-Time Polymerase Chain ReactionAntiviral Agents03 medical and health sciencesImmunocompromised HostmedicineHumanssurveyIntensive care medicineImmunosuppression TherapyTransplantationPhysicians'business.industryDNAOrgan TransplantationAntibiotic Prophylaxismedicine.diseaseMolecular diagnosticsTransplant RecipientsCytomegalovirus infectionTransplantationcytomegalovirus; solid organ transplantation; survey; Transplantation; Infectious DiseasesCross-Sectional StudiesCytomegalovirus; Solid organ transplantation; Survey; Transplantation; Infectious DiseasesHealth Care SurveysDNA ViralImmunologySolid organ transplantationbusinessImmunosuppression
researchProduct